Improving the assessment of erlotinib-induced rashes: a key to early detection and effective management.

摘要

Iia et al present a meta-analysis of the risk of skin rash associated with the use of erlotinib ..... (Tarceva), an epidermal growth factor recep-tor (EGFR) inhibitor, in cancer patients. In addition to being effective inhibitors of tumor growth, this class of drugs is generally well tolerated, without many of the systemic side effects that occur with other chemotherapeutic agents. However, the adverse cutaneous reactions pose a potential threat to the increasing use of these drugs.